Beta Bionics: Funding, Investors & Team (Sep 2026)
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community. Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.
Beta Bionics has raised $117M across 2 funding rounds on record, the most recent a Series E of $60.0M announced in Nov 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Beta Bionics Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Beta Bionics Funding Rounds
Beta Bionics raised $57.0M in a Series C announced in Feb 2022.
2.8 years later, a Series E of $60.0M was announced in Nov 2024.
Beta Bionics Founders and Leadership Team
Contact details for the Beta Bionics team: 2 of 2 have an email address on file.
Start 14-day free trial →Beta Bionics Funding Compared to Other Biotechnology Startups
Beta Bionics' latest round of $60.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Beta Bionics in Biotechnology and Boston
Companies Similar to Beta Bionics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Beta Bionics Funding FAQs
What does Beta Bionics do?
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community. Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.
How much funding has Beta Bionics raised?
Beta Bionics has raised $117M across 2 rounds on record. The most recent is a Series E of $60.0M announced in Nov 2024.
When did Beta Bionics last raise funding?
Beta Bionics' most recent funding round on record is a Series E of $60.0M, announced in Nov 2024.
Who founded Beta Bionics?
FundedIQ lists Sean Saint (Founder) at Beta Bionics.
Who is the CEO of Beta Bionics?
Ed Damiano is listed as CEO at Beta Bionics.
Where is Beta Bionics headquartered?
Beta Bionics is based in Boston, Massachusetts, United States.
How many employees does Beta Bionics have?
Beta Bionics is in the 101-250 employee band.
How does Beta Bionics' funding compare to other Biotechnology startups?
Beta Bionics' latest round of $60.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Beta Bionics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Beta Bionics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.